Go Pro
→ Trump’s New Currency Reset (From Porter & Company) (Ad)tc pixel Free ASBP Stock Alerts

Aspire Biopharma (ASBP) Financials

Aspire Biopharma logo
$7.26 +0.05 (+0.69%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$7.09 -0.17 (-2.38%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Aspire Biopharma

Annual Income Statements for Aspire Biopharma

This table shows Aspire Biopharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 3.34 4.46 -1.31 -24
Consolidated Net Income / (Loss)		 3.34 4.46 -1.31 -24
Net Income / (Loss) Continuing Operations		 3.34 4.46 -1.31 -24
Total Pre-Tax Income 		3.34 4.46 -1.31 -24
Total Operating Income		 -0.98 -1.34 -1.21 -19
Total Gross Profit		 0.00 0.00 0.00 -0.00
Total Revenue		 0.00 0.00 0.00 0.01
Operating Revenue		 - - 0.00 0.01
Total Cost of Revenue		 0.00 0.00 0.00 0.01
Operating Cost of Revenue		 - - 0.00 0.01
Total Operating Expenses		 0.98 1.34 1.21 19
Selling, General & Admin Expense		 0.98 1.34 0.94 18
Marketing Expense		 - - 0.13 0.79
Research & Development Expense		 - - 0.14 0.92
Total Other Income / (Expense), net		 4.32 5.80 -0.10 -5.13
Interest Expense		 0.00 0.01 0.10 8.90
Other Income / (Expense), net		 - - 0.00 3.86
Income Tax Expense		 - - 0.00 0.00
Weighted Average Basic Shares Outstanding		 31.68M 500.97M 689.91K 1.49M
Diluted Earnings per Share		 $0.22 $0.00 ($1.90) ($16.38)
Weighted Average Diluted Shares Outstanding		 31.68M 500.97M 689.91K 1.49M
Weighted Average Basic & Diluted Shares Outstanding		 35.94M 8.99M - 5.02M

Quarterly Income Statements for Aspire Biopharma

This table shows Aspire Biopharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -0.07 -0.15 -0.23 -0.10 -0.22 -0.77 -16 -1.98 -1.85 -4.71 -3.22
Consolidated Net Income / (Loss)		 -0.07 -0.15 -0.23 -0.10 -0.22 -0.77 -16 -1.98 -1.85 -4.71 -3.22
Net Income / (Loss) Continuing Operations		 -0.07 -0.15 -0.23 -0.10 -0.22 -0.77 -16 -1.98 -1.85 -4.71 -3.22
Total Pre-Tax Income 		-0.07 -0.15 -0.23 -0.10 -0.22 -0.77 -16 -1.98 -1.85 -4.71 -3.22
Total Operating Income		 -0.32 -0.40 -0.23 -0.10 -0.22 -0.67 -16 -0.80 -1.15 -1.85 -1.65
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 -0.00 0.01
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.03
Operating Revenue		 - - - - 0.00 - 0.00 - 0.00 - 0.03
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.01 0.02
Operating Cost of Revenue		 - - - - 0.00 - 0.00 - 0.00 - 0.02
Total Operating Expenses		 0.32 0.40 0.23 0.10 0.22 0.67 16 0.80 1.15 1.85 1.65
Selling, General & Admin Expense		 0.32 0.40 0.13 0.09 0.19 0.53 15 0.40 0.51 1.66 1.02
Marketing Expense		 - - 0.09 0.00 0.02 0.02 0.22 0.05 0.43 0.09 0.33
Research & Development Expense		 - - 0.01 0.01 0.01 0.12 0.26 0.35 0.21 0.10 0.30
Total Other Income / (Expense), net		 0.26 0.25 0.00 0.00 0.00 -0.10 -0.38 -1.18 -0.70 -2.86 -1.58
Interest Expense		 - - 0.00 0.00 0.00 0.10 0.29 0.89 1.48 6.23 1.83
Interest & Investment Income		 0.26 0.26 - - - - 0.00 - - - 0.01
Other Income / (Expense), net		 0.00 - 0.00 0.00 0.00 - -0.09 -0.29 0.78 3.47 0.25
Income Tax Expense		 - - - - 0.00 - 0.00 - 0.00 - 0.00
Basic Earnings per Share		 ($0.01) ($0.33) ($0.01) $0.00 ($0.01) ($1.11) ($504.88) ($0.04) ($0.04) ($3.15) ($20.57)
Weighted Average Basic Shares Outstanding		 8.99M 500.97M 27.60M 27.60M 27.60M 689.91K 31.58K 49.33M 49.53M 1.49M 156.69K
Diluted Earnings per Share		 ($0.01) ($0.33) ($0.01) $0.00 ($0.01) ($1.11) ($504.88) ($0.04) ($0.04) ($3.15) ($20.57)
Weighted Average Diluted Shares Outstanding		 8.99M 500.97M 27.60M 27.60M 27.60M 689.91K 31.58K 49.33M 49.53M 1.49M 156.69K
Weighted Average Basic & Diluted Shares Outstanding		 8.99M 8.99M 7.77M 7.77M 7.77M 0.00 49.53M 49.53M 107.48M 5.02M 1.30M

Annual Cash Flow Statements for Aspire Biopharma

This table details how cash moves in and out of Aspire Biopharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.50 -0.50 -0.01 1.00
Net Cash From Operating Activities		 -1.41 -0.65 -0.27 -4.92
Net Cash From Continuing Operating Activities		 -1.41 -0.65 -0.27 -4.92
Net Income / (Loss) Continuing Operations		 3.34 4.46 -1.31 -24
Consolidated Net Income / (Loss)		 3.34 4.46 -1.31 -24
Amortization Expense		 - - 0.00 8.02
Non-Cash Adjustments To Reconcile Net Income		 -4.32 -5.80 0.91 11
Changes in Operating Assets and Liabilities, net		 -0.43 0.69 0.14 0.53
Net Cash From Investing Activities		 -295 285 0.00 0.00
Net Cash From Continuing Investing Activities		 -295 285 0.00 0.00
Net Cash From Financing Activities		 297 -285 0.26 5.92
Net Cash From Continuing Financing Activities		 297 -285 0.26 5.92
Repayment of Debt		 -0.25 0.00 0.00 -3.73
Issuance of Debt		 0.00 0.16 0.00 11
Issuance of Common Equity		 297 - 0.26 0.00
Other Financing Activities, net		 - - 0.00 -0.91
Cash Interest Paid		 - - 0.00 0.04

Quarterly Cash Flow Statements for Aspire Biopharma

This table details how cash moves in and out of Aspire Biopharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -0.12 -0.00 0.04 -0.03 -0.00 -0.01 1.34 -1.14 1.74 -0.94 4.85
Net Cash From Operating Activities		 -0.12 -0.16 -0.19 -0.06 -0.50 0.48 -1.75 -1.14 -1.10 -0.93 -3.04
Net Cash From Continuing Operating Activities		 -0.12 -0.16 -0.19 -0.06 -0.50 0.48 -1.75 -1.14 -1.10 -0.93 -3.04
Net Income / (Loss) Continuing Operations		 -0.07 -0.15 -0.23 -0.10 -0.22 -0.77 -16 -1.98 -1.85 -4.71 -3.22
Consolidated Net Income / (Loss)		 -0.07 -0.15 -0.23 -0.10 -0.22 -0.77 -16 -1.98 -1.85 -4.71 -3.22
Amortization Expense		 - - - - - - 0.00 - - 6.00 1.58
Non-Cash Adjustments To Reconcile Net Income		 -0.26 -0.25 0.00 - - 0.91 15 1.18 -1.59 -3.10 0.01
Changes in Operating Assets and Liabilities, net		 0.20 0.25 0.04 0.04 -0.28 0.34 -0.33 -0.34 0.32 0.88 -1.41
Net Cash From Investing Activities		 0.63 - 0.00 - - - 0.00 - - - 0.00
Net Cash From Continuing Investing Activities		 0.63 - 0.00 - - - 0.00 - - - 0.00
Net Cash From Financing Activities		 -0.63 0.16 0.23 0.03 0.49 -0.49 3.09 - 2.85 -0.02 7.89
Net Cash From Continuing Financing Activities		 -0.63 0.16 0.23 0.03 0.49 -0.49 3.09 - 2.85 -0.02 7.89
Repayment of Debt		 - - 0.00 - - - 0.04 - -3.28 -0.50 -3.06
Issuance of Debt		 - - 0.00 - 0.49 -0.49 3.05 - 7.52 - 2.00
Issuance of Common Equity		 - - 0.23 0.03 - - 0.00 - - - 8.95
Cash Interest Paid		 - - - - - - 0.00 - - - 0.00

Annual Balance Sheets for Aspire Biopharma

This table presents Aspire Biopharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.29 300 20 0.15 1.31
Total Current Assets		 0.29 1.10 0.13 0.15 1.31
Cash & Equivalents		 0.00 0.50 0.01 0.00 1.00
Inventories, net		 - - - 0.00 0.25
Prepaid Expenses		 0.00 0.60 0.12 0.14 0.06
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.00 299 20 0.00 0.00
Other Noncurrent Operating Assets		 0.00 299 20 0.00 0.00
Total Liabilities & Shareholders' Equity		 0.29 300 20 0.15 1.31
Total Liabilities		 0.29 11 0.94 1.69 7.69
Total Current Liabilities		 0.29 0.30 0.94 1.69 7.59
Short-Term Debt		 0.24 0.00 0.37 1.27 2.68
Accounts Payable		 0.00 0.18 0.32 0.31 1.01
Accrued Expenses		 0.05 - - 0.00 1.01
Other Current Liabilities		 0.00 0.12 0.24 0.11 2.89
Total Noncurrent Liabilities		 0.00 11 0.00 0.00 0.10
Other Noncurrent Operating Liabilities		 0.00 11 - 0.00 0.10
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -0.00 -9.94 -0.81 -1.54 -6.38
Total Preferred & Common Equity		 -0.00 -9.94 -0.81 -1.54 -6.38
Preferred Stock		 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -0.00 -9.94 -0.81 -1.54 -6.38
Common Stock		 0.03 0.00 12 1.24 21
Retained Earnings		 -0.03 -9.94 -13 -2.78 -27
Other Equity Adjustments		 - - - - 0.00

Quarterly Balance Sheets for Aspire Biopharma

This table presents Aspire Biopharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 20 20 6.87 6.66 1.97 0.99 2.40 7.12
Total Current Assets		 0.25 0.07 0.34 0.06 1.97 0.99 2.40 7.12
Cash & Equivalents		 0.00 - - - 1.35 0.21 1.95 5.86
Inventories, net		 - - - - - - 0.04 0.37
Prepaid Expenses		 0.25 0.07 0.04 0.04 0.62 0.78 0.42 0.89
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 20 20 6.52 6.60 0.00 0.00 0.00 0.00
Other Noncurrent Operating Assets		 20 20 6.52 6.60 0.00 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity		 20 20 6.87 6.66 1.97 0.99 2.40 7.12
Total Liabilities		 0.32 2.63 6.24 6.57 9.92 11 14 3.25
Total Current Liabilities		 0.32 2.63 6.24 6.57 9.87 11 14 3.15
Short-Term Debt		 - 0.22 0.43 0.44 4.89 5.45 6.12 0.50
Accounts Payable		 0.10 0.37 0.58 0.90 1.43 1.35 1.06 0.86
Accrued Expenses		 - - - - 0.32 0.38 0.27 0.44
Other Current Liabilities		 0.21 2.05 5.23 5.23 3.23 3.38 6.41 1.35
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.05 0.05 0.01 0.10
Other Noncurrent Operating Liabilities		 0.00 - - - 0.05 0.05 0.01 0.10
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -0.06 -2.57 -5.90 -6.51 -7.95 -9.62 -11 3.87
Total Preferred & Common Equity		 -0.06 -2.57 -5.90 -6.51 -7.95 -9.62 -11 3.87
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -0.06 -2.57 -5.90 -6.51 -7.95 -9.62 -11 3.87
Common Stock		 11 11 8.86 8.86 11 11 11 34
Retained Earnings		 -11 -14 -15 -15 -19 -21 -23 -30
Other Equity Adjustments		 - - - - - - - 0.00

Annual Metrics And Ratios for Aspire Biopharma

This table displays calculated financial ratios and metrics derived from Aspire Biopharma's official financial filings.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 35,937,500.00 8,991,229.00 7,765,144.00 214,954,356.00
DEI Adjusted Shares Outstanding		 898,438.00 224,781.00 6,471.00 179,129.00
DEI Earnings Per Adjusted Shares Outstanding		 3.72 19.86 -202.42 -136.67
Growth Metrics		 - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -37.26% 9.65% -516.99%
EBIT Growth		 0.00% -37.26% 9.65% -1,179.28%
NOPAT Growth		 0.00% -37.26% 36.75% -1,498.13%
Net Income Growth		 0.00% 33.65% -129.34% -1,768.95%
EPS Growth		 0.00% -100.00% -129.34% -1,768.95%
Operating Cash Flow Growth		 0.00% 53.64% 59.40% -1,756.62%
Free Cash Flow Firm Growth		 0.00% 0.00% -92.95% -148.29%
Invested Capital Growth		 0.00% -93.26% -101.42% -1,599.23%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 219.53%
EBITDA Q/Q Growth		 0.00% -7.08% -28.03% 64.86%
EBIT Q/Q Growth		 0.00% -7.08% -28.03% 27.13%
NOPAT Q/Q Growth		 0.00% -7.08% -28.03% 8.97%
Net Income Q/Q Growth		 0.00% -34.78% -88.45% -2.14%
EPS Q/Q Growth		 0.00% -100.00% -88.45% -2.14%
Operating Cash Flow Q/Q Growth		 0.00% -22.57% 70.56% 7.20%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 2.68% -29.09%
Invested Capital Q/Q Growth		 0.00% -0.63% -152.58% 35.47%
Profitability Metrics		 - - - -
Gross Margin		 0.00% 0.00% 0.00% -1.87%
EBITDA Margin		 0.00% 0.00% 0.00% -120,460.40%
Operating Margin		 0.00% 0.00% 0.00% -312,016.95%
EBIT Margin		 0.00% 0.00% 0.00% -249,764.62%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% -394,725.06%
Tax Burden Percent		 100.00% 100.00% 100.08% 100.00%
Interest Burden Percent		 -342.12% -333.10% 108.09% 158.04%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 2.31% 2.90% -14.93% 618.48%
Cash Return on Invested Capital (CROIC)		 0.00% 173.87% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% -2,121.75%
Return on Assets (ROA)		 0.00% 0.00% 0.00% -3,353.18%
Return on Common Equity (ROCE)		 -0.08% -0.10% 2.00% 618.48%
Return on Equity Simple (ROE_SIMPLE)		 -33.61% -551.14% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.98 -1.34 -0.85 -14
NOPAT Margin		 0.00% 0.00% 0.00% -218,411.86%
Net Nonoperating Expense Percent (NNEP)		 868.08% 8,572.66% 56.89% 745.26%
Return On Investment Capital (ROIC_SIMPLE)		 - 306.71% 310.19% 366.00%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 101.87%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 284,382.97%
R&D to Revenue		 0.00% 0.00% 0.00% 14,897.03%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 312,015.08%
Earnings before Interest and Taxes (EBIT)		 -0.98 -1.34 -1.21 -15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.98 -1.34 -1.21 -7.47
Valuation Ratios		 - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 2,285.75
Price to Earnings (P/E)		 110.82 21.93 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.90% 4.56% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2.32 6.08 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 2,555.24
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.44 4.80 0.00
Leverage & Solvency		 - - - -
Debt to Equity		 0.00 0.02 -0.82 -0.42
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 0.00 0.09 -0.37
Leverage Ratio		 1.04 1.04 1.15 -0.18
Compound Leverage Factor		 -3.56 -3.46 1.24 -0.29
Debt to Total Capital		 0.00% 1.92% -463.61% -72.28%
Short-Term Debt to Total Capital		 0.00% 1.92% -463.61% -72.28%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 103.44% 102.24% 0.00% 0.00%
Common Equity to Total Capital		 -3.44% -4.16% 563.61% 172.28%
Debt to EBITDA		 0.00 -0.28 -1.05 -0.36
Net Debt to EBITDA		 0.00 -0.27 -1.04 -0.22
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.28 -1.49 -0.20
Net Debt to NOPAT		 0.00 -0.27 -1.49 -0.12
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00
Altman Z-Score		 19.93 61.51 -34.02 -72.67
Noncontrolling Interest Sharing Ratio		 103.44% 103.49% 113.39% 0.00%
Liquidity Ratios		 - - - -
Current Ratio		 3.62 0.14 0.09 0.17
Quick Ratio		 1.64 0.01 0.00 0.13
Cash Flow Metrics		 - - - -
Free Cash Flow to Firm (FCFF)		 0.00 268 19 -9.12
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 29,865.68 192.70 -1.03
Operating Cash Flow to Interest Expense		 0.00 -72.84 -2.71 -0.55
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -72.84 -2.71 -0.55
Efficiency Ratios		 - - - -
Asset Turnover		 0.00 0.00 0.00 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.01
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 38,261.91
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 -38,261.91
Capital & Investment Metrics		 - - - -
Invested Capital		 289 19 -0.28 -4.70
Invested Capital Turnover		 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -269 -20 -4.43
Enterprise Value (EV)		 669 118 91 16
Market Capitalization		 370 98 89 14
Book Value per Share		 ($0.28) ($0.09) ($0.20) ($0.06)
Tangible Book Value per Share		 ($0.28) ($0.09) ($0.20) ($0.06)
Total Capital		 289 19 -0.27 -3.70
Total Debt		 0.00 0.37 1.27 2.68
Total Long-Term Debt		 0.00 0.00 0.00 0.00
Net Debt		 -0.50 0.36 1.26 1.67
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.30 -0.45 -0.28 -4.61
Debt-free Net Working Capital (DFNWC)		 0.79 -0.44 -0.27 -3.61
Net Working Capital (NWC)		 0.79 -0.81 -1.54 -6.28
Net Nonoperating Expense (NNE)		 -4.32 -5.80 0.46 11
Net Nonoperating Obligations (NNO)		 -0.50 0.36 1.26 1.67
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 8.02
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% -74,319.85%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% -58,133.07%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% -101,268.41%
Earnings Adjustments		 - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.46 ($1,827.60) $0.00
Adjusted Weighted Average Basic Shares Outstanding		 31.68M 19.18M 429.67K 49.83K
Adjusted Diluted Earnings per Share		 $0.00 $0.46 ($1,827.60) ($491.40)
Adjusted Weighted Average Diluted Shares Outstanding		 31.68M 19.18M 429.67K 49.83K
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 35.94M 8.99M 0.00 167.47K
Normalized Net Operating Profit after Tax (NOPAT)		 -0.68 -0.94 -0.85 -14
Normalized NOPAT Margin		 0.00% 0.00% 0.00% -218,411.86%
Pre Tax Income Margin		 0.00% 0.00% 0.00% -394,725.06%
Debt Service Ratios		 - - - -
EBIT to Interest Expense		 0.00 -149.47 -12.36 -1.74
NOPAT to Interest Expense		 0.00 -149.47 -8.65 -1.52
EBIT Less CapEx to Interest Expense		 0.00 -149.47 -12.36 -1.74
NOPAT Less CapEx to Interest Expense		 0.00 -149.47 -8.65 -1.52
Payout Ratios		 - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 8.94% 6,382.42% 0.00% 0.00%

Quarterly Metrics And Ratios for Aspire Biopharma

This table displays calculated financial ratios and metrics derived from Aspire Biopharma's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 8,991,229.00 8,991,229.00 8,991,229.00 7,765,144.00 7,765,144.00 7,765,144.00 7,765,144.00 99,051,940.00 49,525,970.00 214,954,356.00 10,048,248.00
DEI Adjusted Shares Outstanding		 224,781.00 224,781.00 224,781.00 194,129.00 194,129.00 6,471.00 6,471.00 2,476,299.00 1,238,149.00 179,129.00 334,942.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.31 -0.67 -1.03 -0.50 -1.11 -118.33 -2,463.50 -0.80 -1.49 -26.28 -9.62
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -27.22% -28.21% 28.84% 66.37% 33.71% -65.85% -6,676.38% -1,023.87% -72.09% 1,241.04% 101.21%
EBIT Growth		 -27.22% -28.21% 28.84% 66.37% 33.71% -65.85% -6,676.38% -1,023.87% -72.09% 342.72% 91.09%
NOPAT Growth		 10.94% 10.25% 50.19% 76.46% 33.71% -65.85% -6,635.28% -725.28% -432.16% -176.98% 89.42%
Net Income Growth		 -106.43% -106.77% -108.04% -105.35% -212.27% -407.39% -6,801.90% -1,944.19% -755.64% -514.82% 79.78%
EPS Growth		 -116.67% -306.25% -106.25% -100.00% 0.00% -407.39% -6,801.90% 0.00% -300.00% -514.82% 79.78%
Operating Cash Flow Growth		 -167.94% -335.26% -5.97% 70.39% -296.68% 407.16% -807.66% -1,927.43% -122.75% -293.47% -73.48%
Free Cash Flow Firm Growth		 193.00% 0.00% 4,050.28% -92.81% -92.91% -92.83% -95.87% -74.41% -62.88% -83.73% -136.04%
Invested Capital Growth		 -93.16% -93.26% -93.90% -94.77% -97.31% -101.42% -124.81% -514.65% -1,484.59% -1,599.23% 66.25%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 119.53% 565.41%
EBITDA Q/Q Growth		 -12.66% -23.98% 42.63% 58.04% -122.09% -210.20% -2,244.00% 93.04% 65.99% 2,156.76% -97.51%
EBIT Q/Q Growth		 -12.66% -23.98% 42.63% 58.04% -122.09% -210.20% -2,244.00% 93.04% 65.99% 537.52% -186.03%
NOPAT Q/Q Growth		 21.14% -23.98% 42.63% 58.04% -122.09% -210.20% -2,229.78% 94.86% -43.21% -61.45% 10.99%
Net Income Q/Q Growth		 -103.82% -117.90% -53.05% 58.04% -123.13% -254.05% -1,981.90% 87.57% 6.60% -154.40% 31.54%
EPS Q/Q Growth		 -105.56% -3,200.00% 96.97% 100.00% 0.00% -254.05% -1,981.90% 90.48% 0.00% -154.40% 31.54%
Operating Cash Flow Q/Q Growth		 34.24% -24.98% -23.60% 70.85% -781.05% 196.78% -465.23% 34.90% 3.20% 15.94% -227.48%
Free Cash Flow Firm Q/Q Growth		 0.67% 0.88% 1.80% -93.05% -0.69% 1.92% -41.29% -52.76% 44.05% -55.33% -230.09%
Invested Capital Q/Q Growth		 -2.86% -0.63% -8.57% -94.07% -50.09% -152.58% -1,493.91% -28.17% -66.65% 35.47% 68.35%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 45.54% -23.47% 20.28%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -19,084.75% 178,806.85% 668.46%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -59,015.82% -43,403.52% -5,805.98%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -19,084.75% 38,036.17% -4,917.86%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -95,337.09% -110,484.25% -11,367.02%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.47% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 21.33% 37.48% 100.00% 100.00% 100.00% 114.68% 101.85% 181.89% 499.55% -290.47% 231.14%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 4.47% 2.90% 0.88% -5.24% -7.07% -14.93% -354.02% 496.90% 421.35% 618.48% 575.98%
Cash Return on Invested Capital (CROIC)		 0.00% 173.87% 176.20% 173.14% 182.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8.17% 323.12% -37.42%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -40.82% -938.56% -86.49%
Return on Common Equity (ROCE)		 -0.14% -0.10% -0.04% 1.41% 2.36% 2.00% 387.34% 857.55% 665.83% 618.48% 575.98%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.23 -0.28 -0.16 -0.07 -0.15 -0.47 -11 -0.56 -0.80 -1.29 -1.15
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -41,311.07% -30,382.46% -4,064.18%
Net Nonoperating Expense Percent (NNEP)		 59.26% 193.36% -141.53% 19.22% 30.09% 36.71% 268.96% 50.14% 45.47% 232.62% -227.73%
Return On Investment Capital (ROIC_SIMPLE)		 - 64.50% 6.88% 1.24% 2.48% 171.05% 355.07% 13.43% 15.01% 34.98% -26.38%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 54.46% 123.47% 79.72%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 26,429.31% 38,845.32% 3,599.11%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 10,710.92% 2,347.69% 1,046.53%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 59,061.36% 43,380.05% 5,826.26%
Earnings before Interest and Taxes (EBIT)		 -0.32 -0.40 -0.23 -0.10 -0.22 -0.67 -16 -1.09 -0.37 1.62 -1.39
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.32 -0.40 -0.23 -0.10 -0.22 -0.67 -16 -1.09 -0.37 7.62 0.19
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.34
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.34
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5,256.23 2,285.75 149.76
Price to Earnings (P/E)		 14.23 21.93 72.79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 7.03% 4.56% 1.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 5.98 6.08 6.71 89.53 193.42 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 7,407.95 2,555.24 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.44 0.44 5.15 5.54 4.80 0.76 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.02 0.01 0.68 4.83 -0.82 -0.61 -0.57 -0.53 -0.42 0.13
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 0.00 0.00 0.01 0.02 0.09 0.39 -0.63 -0.41 -0.37 0.45
Leverage Ratio		 1.04 1.04 1.04 1.31 1.35 1.15 2.31 -0.87 -0.80 -0.18 -2.22
Compound Leverage Factor		 0.22 0.39 1.04 1.31 1.35 1.32 2.35 -1.59 -3.98 0.54 -5.14
Debt to Total Capital		 0.00% 1.92% 1.22% 40.55% 82.85% -463.61% -159.31% -130.69% -114.64% -72.28% 11.43%
Short-Term Debt to Total Capital		 0.00% 1.92% 1.22% 40.55% 82.85% -463.61% -159.31% -130.69% -114.64% -72.28% 11.43%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 100.32% 102.24% 113.22% 618.39% 1,253.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -0.32% -4.16% -14.44% -558.94% -1,236.51% 563.61% 259.31% 230.69% 214.64% 172.28% 88.57%
Debt to EBITDA		 0.00 -0.28 -0.17 -0.41 -0.46 -1.05 -0.29 -0.27 -0.29 -0.36 0.06
Net Debt to EBITDA		 0.00 -0.27 -0.17 -0.41 -0.46 -1.04 -0.21 -0.26 -0.20 -0.22 -0.64
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.28 -0.17 -0.58 -0.66 -1.49 -0.42 -0.38 -0.41 -0.20 -0.13
Net Debt to NOPAT		 0.00 -0.27 -0.17 -0.58 -0.66 -1.49 -0.31 -0.37 -0.28 -0.12 1.41
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 183.88 61.67 21.41 4.33 4.15 -21.91 -44.16 -43.77 -18.93 -29.64 -5.01
Noncontrolling Interest Sharing Ratio		 103.16% 103.49% 104.15% 126.96% 133.43% 113.39% 209.41% -72.58% -58.02% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.80 0.14 0.02 0.06 0.01 0.09 0.20 0.09 0.17 0.17 2.26
Quick Ratio		 0.00 0.01 0.00 0.05 0.00 0.00 0.14 0.02 0.14 0.13 1.86
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 266 269 274 19 19 19 11 4.87 7.02 3.13 -4.08
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 196.58 39.01 5.46 4.74 0.50 -2.22
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 4.89 -6.04 -1.28 -0.75 -0.15 -1.66
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 4.89 -6.04 -1.28 -0.75 -0.15 -1.66
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.03
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 339,200.68 38,261.91 14,450.26
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -339,200.68 -38,261.91 -14,450.26
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 20 19 18 1.06 0.53 -0.28 -4.41 -4.37 -7.29 -4.70 -1.49
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01
Increase / (Decrease) in Invested Capital		 -267 -269 -274 -19 -19 -20 -22 -5.43 -7.82 -4.43 2.92
Enterprise Value (EV)		 117 118 119 94 102 91 8.06 19 14 16 -0.18
Market Capitalization		 97 98 99 88 95 89 4.52 13 10 14 5.17
Book Value per Share		 ($0.01) ($0.09) ($0.29) ($0.76) ($0.84) ($0.20) ($1.02) ($0.19) ($0.23) ($0.06) $0.77
Tangible Book Value per Share		 ($0.01) ($0.09) ($0.29) ($0.76) ($0.84) ($0.20) ($1.02) ($0.19) ($0.23) ($0.06) $0.77
Total Capital		 20 19 18 1.06 0.53 -0.27 -3.07 -4.17 -5.34 -3.70 4.37
Total Debt		 0.00 0.37 0.22 0.43 0.44 1.27 4.89 5.45 6.12 2.68 0.50
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -0.00 0.36 0.22 0.43 0.44 1.26 3.54 5.24 4.18 1.67 -5.36
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.06 -0.45 -2.35 -5.47 -6.07 -0.28 -4.36 -4.33 -7.28 -4.61 -1.39
Debt-free Net Working Capital (DFNWC)		 -0.06 -0.44 -2.35 -5.47 -6.07 -0.27 -3.02 -4.12 -5.33 -3.61 4.46
Net Working Capital (NWC)		 -0.06 -0.81 -2.57 -5.90 -6.51 -1.54 -7.90 -9.57 -11 -6.28 3.96
Net Nonoperating Expense (NNE)		 -0.16 -0.13 0.07 0.03 0.07 0.30 5.05 1.42 1.05 3.41 2.07
Net Nonoperating Obligations (NNO)		 -0.00 0.36 0.22 0.43 0.44 1.26 3.54 5.24 4.18 1.67 -5.36
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.00 1.58
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -375,111.03% -74,319.85% -4,031.53%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -274,736.42% -58,133.07% 12,918.33%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -590,282.17% -101,268.41% 11,473.64%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.33) ($0.27) ($0.07) ($0.07) ($1,332.00) $0.00 ($0.04) ($0.04) ($3,780.00) ($20.57)
Adjusted Weighted Average Basic Shares Outstanding		 8.99M 500.97M 8.99M 8.47M 7.77M 575.00 0.00 49.33M 49.53M 1.25K 156.69K
Adjusted Diluted Earnings per Share		 $0.00 ($0.33) ($0.27) ($0.07) ($0.07) ($1,332.00) $0.00 ($0.04) ($0.04) ($3,780.00) ($20.57)
Adjusted Weighted Average Diluted Shares Outstanding		 8.99M 500.97M 8.99M 8.47M 7.77M 575.00 0.00 49.33M 49.53M 1.25K 156.69K
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 ($1,332.00) $0.00 $0.00 $0.00 ($3,780.00) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 8.99M 8.99M 7.77M 7.77M 7.77M 0.00 0.00 49.53M 107.48M 4.19K 1.30M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.23 -0.28 -0.16 -0.07 -0.15 -0.47 -11 -0.56 -0.80 -1.29 -1.15
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -41,311.07% -30,382.46% -4,064.18%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -95,337.09% -110,484.25% -11,367.02%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -6.81 -53.98 -1.22 -0.25 0.26 -0.76
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -4.77 -37.56 -0.63 -0.54 -0.21 -0.63
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -6.81 -53.98 -1.22 -0.25 0.26 -0.76
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -4.77 -37.56 -0.63 -0.54 -0.21 -0.63
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 4,162.31% 6,382.42% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Aspire Biopharma Holdings (NASDAQ: ASBP) showed a sharp improvement in liquidity in Q1 2026, but the business still appears highly dependent on external financing and continues to post meaningful operating losses. Revenue jumped year over year, yet expenses and interest costs remain far above gross profit, keeping the company deep in the red.

Top takeaways from the last several quarters:

  • Q1 2026 revenue rose to $28,353 from $1,941 in Q3 2025 and $0 in several earlier quarters, showing early commercial traction.
  • Cash and equivalents climbed to $5.9 million at the end of Q1 2026, up from $1.9 million in Q3 2025 and $206,233 in Q2 2025.
  • The company raised significant capital in Q1 2026, including $8.95 million from common equity issuance and $2.0 million from debt issuance.
  • Operating cash flow improved sequentially from -$927,841 in Q4 2025 to -$3.0 million in Q1 2026, but financing inflows more than offset the burn.
  • Gross profit turned positive in Q1 2026 at $5,750, compared with a gross loss in Q4 2025.
  • Quarterly revenue has been inconsistent and still very small, so it is too early to call the business model proven.
  • The company carries a large accumulated deficit, with retained earnings at -$30.5 million in Q1 2026.
  • Balance sheet equity improved to $3.9 million in Q1 2026 from a negative position in prior quarters, largely because of capital raises rather than sustained profitability.
  • Q1 2026 net loss was still substantial at -$3.2 million, or -$20.57 per share.
  • Operating expenses of $1.65 million far exceeded gross profit in Q1 2026, leaving operating income at -$1.65 million.
  • Interest expense was heavy at $1.83 million in Q1 2026, contributing to a pre-tax loss of -$3.22 million.
  • Current liabilities of $3.15 million remain significant relative to current assets of $7.12 million, and the company still depends on financing to support operations.
  • The historical trend shows persistent losses across 2024 and 2025, including a steep restated Q1 2025 loss of -$15.9 million.

Bottom line: ASBP appears to have improved its cash position and finally generated modest revenue, which are encouraging signs. However, the company is still far from profitability, and its financial profile suggests a high-risk, dilution-prone story where future execution and access to capital will matter more than current earnings.

07/26/26 08:04 PM ETAI Generated. May Contain Errors.

Aspire Biopharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Aspire Biopharma's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Aspire Biopharma's net income appears to be on an upward trend, with a most recent value of -$24.48 million in 2025, falling from $3.34 million in 2022. The previous period was -$1.31 million in 2024. See Aspire Biopharma's forecast for analyst expectations on what's next for the company.

Aspire Biopharma's total operating income in 2025 was -$19.35 million, based on the following breakdown:
  • Total Gross Profit: -$116.00
  • Total Operating Expenses: $19.35 million

Over the last 3 years, Aspire Biopharma's total revenue changed from $0.00 in 2022 to $6.20 thousand in 2025, a change of 620,200.0%.

Aspire Biopharma's total liabilities were at $7.69 million at the end of 2025, a 355.5% increase from 2024, and a 2,517.8% increase since 2021.

In the past 4 years, Aspire Biopharma's cash and equivalents has ranged from $0.00 in 2021 to $1.00 million in 2025, and is currently $1.00 million as of their latest financial filing in 2025.

Over the last 3 years, Aspire Biopharma's book value per share changed from -0.28 in 2022 to -0.06 in 2025, a change of -78.6%.


Related Companies

Financial statements for NASDAQ:ASBP last updated on 7/22/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The pact that ran the world and dollar just expired
In 1974, a U.S.-Saudi deal tied oil sales exclusively to dollars, forcing nations worldwide to hold dollars an...
Golden Portfolio | Sponsoredtc pixel
Control 100 shares without spending thousands of dollars
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
BlackRock's $2.8B Clue (most investors missed)
BlackRock's new fund on the emerging financial grid hit 2.8 billion in assets in just three months, according ...
Awesomely | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
Universal basic income is not impossible. It exist (kind of)
Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...
Freedom Financial | Sponsoredtc pixel
Oxford Club Analyst’s Urgent AI Warning
Alexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...
The Oxford Club | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel